[Elsevier] Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

velt Post time 1 hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-06-18 00:14
Reward10points


Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Junior Member
  • post

  • reply

  • points

    20


Daily Top Contributors

Return to the list